Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
$0.17
-24.7%
$0.28
$0.12
$2.90
N/AN/A8,411 shs3,296 shs
Genetron Holdings Limited stock logo
GTH
Genetron
$4.03
$3.98
$2.08
$4.05
$127.27M0.5151,662 shs412,603 shs
PRENW
Prenetics Global
$0.01
$0.01
$0.01
$0.02
N/AN/A79,365 shs2,134 shs
SQLLW
SeqLL
$0.01
$0.01
$0.00
$0.11
N/AN/A9,750 shsN/A
10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
0.00%-10.94%-21.56%-56.38%-62.00%
Genetron Holdings Limited stock logo
GTH
Genetron
0.00%0.00%-0.12%-0.12%-0.12%
PRENW
Prenetics Global
0.00%0.00%-3.85%+14.29%+28.21%
SQLLW
SeqLL
0.00%0.00%0.00%+228.50%+238.66%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
Genetron Holdings Limited stock logo
GTH
Genetron
N/AN/AN/AN/AN/AN/AN/AN/A
PRENW
Prenetics Global
N/AN/AN/AN/AN/AN/AN/AN/A
SQLLW
SeqLL
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
0.00
N/AN/AN/A
Genetron Holdings Limited stock logo
GTH
Genetron
0.00
N/AN/AN/A
PRENW
Prenetics Global
0.00
N/AN/AN/A
SQLLW
SeqLL
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
$9.36MN/AN/AN/AN/AN/A
Genetron Holdings Limited stock logo
GTH
Genetron
$94.34M1.35N/AN/A$2.63 per share1.53
PRENW
Prenetics Global
$25.56MN/AN/AN/AN/AN/A
SQLLW
SeqLL
$1.18KN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
N/AN/A0.00N/AN/AN/AN/AN/A
Genetron Holdings Limited stock logo
GTH
Genetron
-$117.21MN/A0.00N/AN/AN/AN/AN/A
PRENW
Prenetics Global
N/AN/A0.00N/AN/AN/AN/AN/A
SQLLW
SeqLL
N/AN/A0.00N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
N/AN/AN/AN/AN/A
Genetron Holdings Limited stock logo
GTH
Genetron
N/AN/AN/AN/AN/A
PRENW
Prenetics Global
N/AN/AN/AN/AN/A
SQLLW
SeqLL
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
N/A
Genetron Holdings Limited stock logo
GTH
Genetron
10.74%
PRENW
Prenetics Global
N/A
SQLLW
SeqLL
N/A

Insider Ownership

CompanyInsider Ownership
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
N/A
Genetron Holdings Limited stock logo
GTH
Genetron
N/A
PRENW
Prenetics Global
N/A
SQLLW
SeqLL
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
10N/AN/ANot Optionable
Genetron Holdings Limited stock logo
GTH
Genetron
99331.62 millionN/ANot Optionable
PRENW
Prenetics Global
1N/AN/ANot Optionable
SQLLW
SeqLL
7N/AN/ANot Optionable

Recent News About These Companies

No headlines for this company have been tracked by MarketBeat.com

Media Sentiment Over Time

Top Headlines

View All Headlines
bioAffinity Technologies stock logo

bioAffinity Technologies NASDAQ:BIAFW

$0.17 -0.06 (-24.67%)
As of 04/25/2025 10:43 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.

Genetron stock logo

Genetron NASDAQ:GTH

Genetron Holdings Limited, a precision oncology platform company, focuses on cancer management by utilizing technologies in molecular biology and data science in the People's Republic of China. It offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. The company also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. In addition, it offers IDH1 and TERT gene assays for glioma; thyroid basic assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for GIST cancer; and HCCscan, a qPCR-based assay to detect hepatocellular carcinoma. Further, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies worldwide. Genetron Holdings Limited was founded in 2013 and is headquartered in Beijing, the People's Republic of China.

Prenetics Global NASDAQ:PRENW

$0.01 0.00 (0.00%)
As of 04/25/2025 10:54 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Prenetics Global Limited operates as a diagnostics and genetic testing company in Hong Kong and the United Kingdom. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring device that offers COVID-19 testing solutions for professional use and home use. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; ACTOnco, a comprehensive test that helps clinicians choose the optimal treatment for all major solid tumors; ACTDrug+, a screening test that checks for 40 cancer genes to map drug options and provide treatment strategy options; ACTLung, a test focused on biomarkers associated with lung cancer for targeted therapy; ACTFusion, a test that decodes 13 fusion genes and more than 350 transcripts to map drug options; and ACTCerebra, a genomic profiling service for solid tumors. It also offers ACTMonitor, a test that analyzes 50 forms of circulating tumor DNA in the bloodstream; and ACT Risk, a screening of 67 cancer genes associated with 9 common hereditary cancers and 11 cancer syndromes. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.

SeqLL NASDAQ:SQLLW

$0.0066 0.00 (0.00%)
As of 04/25/2025

SeqLL Inc. operates as a life sciences instrumentation and research services company worldwide. It focus on development of scientific assets and novel intellectual property across multiple omics fields. The company's True Single Molecule Sequencing technology (tSMS) platform offers a single molecule solution for DNA and RNA sequencing through detection of nucleic acids to researchers for analyzing many billions of single molecules in a single experiment and generate accurate and reproducible data. It provide solutions for various applications, such as biomarker discovery and diagnostic assay developments including laboratories associated with universities, scientific research centers, government institutions, and biotechnology and pharmaceutical companies. In addition, the company has research and development agreement with U.S. Department of Justice's Federal Bureau of Investigation to evaluate and determine the forensic capabilities of direct RNA sequencing using tSMS platform; and research collaboration with True Bearing Diagnostics, Inc. performing tSMS on whole-blood RNA to identify transcripts associated with coronary artery disease. Further, it has collaboration agreement with The Bernstein Laboratory to address fundamental questions in chromatin biology and epigenetic regulation; The Ting Laboratory; The Jackson Laboratory for Genomic Medicine assisting in the development of new methods for chromatin interaction analysis in single nuclei, with single-molecule resolution; Weizmann Institute of Science for developed and applied innovative single-molecule technologies; and Tetracore, Inc. to provide with tSMS systems and onsite support. The company was founded in 2013 and is headquartered in Billerica, Massachusetts.